Consistent with previous reports that insoluble tau aggregates are strongly implicated in cognitive decline in AD78, these data provide therapeutic insight that the disturbance of the dynamic equilibrium of tau aggregation by neuronal FGFR3 deficiency could effectively reduce and delay the progression of tau-related AD pathologies. This evidence concerns the gene MAPT and Alzheimer disease.